AstraZeneca Reports Results of Imfinzi (durvalumab) + Tremelimumab in P-III NEPTUNE Study for Stage IV Non-Small Cell Lung Cancer

 AstraZeneca Reports Results of Imfinzi (durvalumab) + Tremelimumab in P-III NEPTUNE Study for Stage IV Non-Small Cell Lung Cancer

AstraZeneca Reports Results of Imfinzi (durvalumab) + Tremelimumab in P-III NEPTUNE Study for Stage IV Non-Small Cell Lung Cancer

Shots:

  • The P-III NEPTUNE study involves assessing of Imfinzi + tremelimumab vs SOC platinum-based CT as a 1L treatment in patients with Stage IV metastatic NSCLC + high tumor mutational burden (TMB) across 29 countries including the US, Europe, South and Central America, the Middle East and Asia.
  • The P-III NEPTUNE study results demonstrated that it did not meet 1EPs i.e, OS in patients with high blood TMB defined as ≥ 20 mut/Mb while its safety and tolerability profile is consistent with previous studies
  • Imfinzi is a mAb targeting PD-L1, blocking its interaction with PD-1 and CD80, currently being evaluated in P-III PEARL study as monothx. and in combination with CT with/out tremelimumab in the P-III POSEIDON for Stage IV NSCLC

Click here to­ read full press release/ article | Ref: AstraZeneca| Image: Coroflot

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post